BenevolentAI

Thank you to everyone who joined our Chief Technology Officer, Dr James Malone, to discuss trust and explainability in using AI in drug discovery. Describing how explainable AI can increase transparency in drug discovery, James presented data that compared the performance of our Retrieve to Explain (R2E) system against traditional approaches in predicting clinical trial outcomes. When utilising all data modalities, James shared that R2E demonstrated a higher relative success rate in identifying promising drug targets compared to industry-leading genetics-based methods. These performance improvements confirm R2E's potential to significantly impact the drug discovery process, particularly in the critical areas of target identification and clinical trial success prediction. 👉 Further information is available here: https://lnkd.in/eXeRpuni As the congress draws to a close, our thanks also goes to all the delegates who attended the Keynote Panel, or joined our expert team at our booth to discuss our proprietary pipeline, innovative industry collaborations and validated AI drug discovery technologies. If you were unable to attend BioTechX Europe and would like to speak with our team, contact us: bd@benevolent.ai #BioTechX

Did you miss the Keynote Panel at BioTechX Europe that explored the benefits of AI in drug discovery? Panel chair Dr Ivan Griffin, our Co-Founder & Chief Business Officer, and Dr James Malone, Chief Technology Officer, were joined by: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD 📺 Catch the session in full now: https://lnkd.in/dbt4_Ybp #BioTechX

Today, we announce the appointment of co-founder Kenneth Mulvany as Executive Chairman. We are also pleased to confirm the return of co-founder Michael Brennan as Chief Strategy and Financial Officer. Kenneth Mulvany comments: “When we founded BenevolentAI, our vision was to harness the power of AI to tackle healthcare's most pressing challenges. We have since developed one of the world's most advanced and validated AI drug discovery and development platforms, achieved the first FDA approval for an AI-identified drug, secured partnerships with global pharmaceutical leaders, and built a robust pipeline of potential first-in-class medicines for unmet medical needs. However, we have only scratched the surface of our platform's incredible potential..." 👉 Read more: https://lnkd.in/eBrWVsCH

Our CEO, Dr Joerg Moeller, M.D., shares his expertise on the real-world value of generative AI as part of WSJ CEO Council: “The pharma and biotech industry still faces over a 90% failure rate in drug development, and 9,000 diseases lack effective treatments.  By integrating data from a vast range of sources—from genetics to clinical trials across all disease areas—generative AI can help us uncover new insights, identify new drug targets and improve success rates while reducing timelines. Patient-driven disease modelling focuses on mechanisms driving tailored medicines, while AI’s agnostic approach helps us overcome challenges even top scientists face.” The feature is available in the print edition of The Wall Street Journal, alongside insights from: 👉 Ken Keller of Daiichi Sankyo US   👉 Brian Becker of RSM US LLP 👉 Revathi Advaithi of Flex #WSJCEOCouncil #CEOExcellence

This weekend, congress season continues apace with the UEG - United European Gastroenterology conference in Vienna. To hear about our novel target for ulcerative colitis and Crohn’s disease, BEN-8744, and discuss its potential, connect onsite with our VP of Clinical Development & Translational Medicine, Judit Molnar MD PhD, or contact our team: bd@benevolent.ai #UEGWeek

Today at BioTechX Europe, our Chief Technology Officer, Dr James Malone, will discuss "Building Trust and Explainability in using AI in Drug Discovery". James will describe how explainable AI can increase transparency in drug discovery, focusing on BenevolentAI's innovative R2E (Retrieve to Explain) system. He'll illustrate the capabilities of R2E, which combines AI-driven information retrieval with explainable predictions to enhance drug target identification. James will also present data comparing R2E's performance against traditional approaches in predicting clinical trial outcomes. More information is available here: https://lnkd.in/eXeRpuni If you're onsite in Basel, join us at 11.45 AM CET in Theatre 3. #BioTechX

Thank you to all the delegates who joined us at today's Keynote Panel to discuss 'The benefits of AI within drug discovery' (and especially those who stood at the back!) The discussion was truly compelling, with a focus on how AI technology is already accelerating innovation to deliver tangible value to pipelines — and how, by solving some of the pharma and biotech industry's greatest R&D challenges, AI holds the promise of delivering better outcomes for patients. Our sincere appreciation to the speakers who joined panel chair Dr Ivan Griffin, Co-Founder & Chief Business Officer, and Dr James Malone, Chief Technology Officer, for the session: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD On Thurs 10 Oct, Dr James Malone will also deliver a presentation titled 'Building trust and explainability in using AI in drug discovery'. Join us at 11.45 AM CET in Theatre 3. #BioTechX

Our BioTechX team is set! Throughout the event, you'll find our experts at Booth 1116. They’re onsite to answer your biggest questions about AI-driven drug discovery, as well as to discuss our proprietary pipeline, innovative industry collaborations and validated AI drug discovery technologies. On Thurs 10 Oct, 11.45 AM CET in Theatre 3, our Chief Technology Officer Dr James Malone will also deliver a presentation titled 'Building trust and explainability in using AI in drug discovery'. #BioTechX

Ready for BioTechX Europe? Set to discuss the event's hot topic with Dr Ivan Griffin, our Co-Founder & Chief Business Officer, and Dr James Malone, Chief Technology Officer, are: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD Join us: Weds 9 October, 10:00 AM — The Keynote Room — for what promises to be a compelling panel discussion. #BioTechX

It's almost time for BioTechX Europe! On 9 October, 10 AM CET, our Co-Founder and Chief Business Officer, Dr Ivan Griffin, will chair 'The benefits of AI within drug discovery' panel discussion. Along with Dr James Malone, our Chief Technology Officer, Ivan will be joined by: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD On 10 October, 11.45 AM CET, Dr James Malone will also deliver a presentation on 'Building trust and explainability in using AI in drug discovery'. Throughout the event, you'll find our expert team at Booth 1116. They're ready to answer your questions about our proprietary pipeline, innovative industry collaborations and validated AI drug discovery technologies. We look forward to seeing you in Basel.